PL3436019T3 - (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahydro-2h-piran-4-ylo)amino)- 8-((2,4,6- trichlorofenylo)amino)-9h-puryn-9-ylo)-1-metylocykloheksano- 1-karboksamid i sposoby ich stosowania - Google Patents

(1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahydro-2h-piran-4-ylo)amino)- 8-((2,4,6- trichlorofenylo)amino)-9h-puryn-9-ylo)-1-metylocykloheksano- 1-karboksamid i sposoby ich stosowania

Info

Publication number
PL3436019T3
PL3436019T3 PL17776743T PL17776743T PL3436019T3 PL 3436019 T3 PL3436019 T3 PL 3436019T3 PL 17776743 T PL17776743 T PL 17776743T PL 17776743 T PL17776743 T PL 17776743T PL 3436019 T3 PL3436019 T3 PL 3436019T3
Authority
PL
Poland
Prior art keywords
amino
fluorotetrahydro
purin
trichlorophenyl
methylcyclohexane
Prior art date
Application number
PL17776743T
Other languages
English (en)
Inventor
Zheng Chen
Paul F. Fernandez
Tracy L. Gaebele
Lianfeng Huang
Matthew J. Jackson
Matthew M. Kreilein
Xiaoling Lu
Wenju Wu
Jean Xu
Original Assignee
Signal Pharmaceuticals, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals, Llc filed Critical Signal Pharmaceuticals, Llc
Publication of PL3436019T3 publication Critical patent/PL3436019T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17776743T 2016-04-01 2017-03-31 (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahydro-2h-piran-4-ylo)amino)- 8-((2,4,6- trichlorofenylo)amino)-9h-puryn-9-ylo)-1-metylocykloheksano- 1-karboksamid i sposoby ich stosowania PL3436019T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317468P 2016-04-01 2016-04-01
EP17776743.1A EP3436019B1 (en) 2016-04-01 2017-03-31 (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahydro-2h-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9h-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use
PCT/US2017/025289 WO2017173218A1 (en) 2016-04-01 2017-03-31 Solid forms of (1s,4s)-4-(2-(((3s4r)-3-fluorotetrahydro-2h-pyran-4-yl) amino)-8-((2,4,6-trichlorophenyl) amino)-9h-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use

Publications (1)

Publication Number Publication Date
PL3436019T3 true PL3436019T3 (pl) 2022-01-10

Family

ID=59960229

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17776743T PL3436019T3 (pl) 2016-04-01 2017-03-31 (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahydro-2h-piran-4-ylo)amino)- 8-((2,4,6- trichlorofenylo)amino)-9h-puryn-9-ylo)-1-metylocykloheksano- 1-karboksamid i sposoby ich stosowania

Country Status (18)

Country Link
US (2) US10047090B2 (pl)
EP (2) EP3436019B1 (pl)
JP (1) JP6995058B2 (pl)
CN (1) CN109819649B (pl)
AU (1) AU2017240050B2 (pl)
CA (1) CA3019105A1 (pl)
CY (1) CY1124677T1 (pl)
DK (1) DK3436019T3 (pl)
ES (1) ES2895419T3 (pl)
HR (1) HRP20211546T1 (pl)
HU (1) HUE056631T2 (pl)
LT (1) LT3436019T (pl)
MX (1) MX2018011970A (pl)
PL (1) PL3436019T3 (pl)
PT (1) PT3436019T (pl)
RS (1) RS62496B1 (pl)
SI (1) SI3436019T1 (pl)
WO (1) WO2017173218A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2963639C (en) 2014-10-06 2023-07-04 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
NZ746554A (en) * 2016-04-01 2023-03-31 Signal Pharm Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
ES2836050T3 (es) * 2016-06-21 2021-06-23 Teva Pharmaceuticals Int Gmbh Formas en estado sólido de citrato de ixazomib
CA3078368A1 (en) 2017-10-04 2019-04-11 Celgene Corporation Compositions and methods of use of cis-4-[2-{[(3s,4r)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide
KR20200061363A (ko) * 2017-10-04 2020-06-02 셀진 코포레이션 시스-4-[2-｛[(3ｓ,4ｒ)-3-플루오로옥산-4-일]아미노｝-8-(2,4,6-트리클로로아닐리노)-9ｈ-퓨린-9-일]-1-메틸사이클로헥산-1-카르복스아미드의 제조 공정

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US20090215744A1 (en) 2005-11-18 2009-08-27 Astrazeneca Ab Solid Formulations
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
MX2009003913A (es) 2006-10-27 2009-04-24 Signal Pharm Llc Formas solidas que comprenden 4-[9-(tetrahidro-furano-3-il)-8-(2,4 ,6-trifluoro-fenilamino)-9h-purin-2-ilamino]-ciclohexan-1-ol, composiciones de las mismas, y su uso.
PT2279731E (pt) 2008-04-23 2013-08-30 Farmasierra Mfg S L Composição farmacêutica melhorada contendo ibuprofeno e codeína
WO2011071491A1 (en) 2009-12-09 2011-06-16 Signal Pharmaceuticals, Llc Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8603527B2 (en) * 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US8680076B2 (en) 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US9466042B2 (en) 2012-01-24 2016-10-11 International Business Machines Corporation Facilitating the design of information technology solutions
WO2014172616A2 (en) 2013-04-18 2014-10-23 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
CA2963639C (en) 2014-10-06 2023-07-04 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
NZ746554A (en) 2016-04-01 2023-03-31 Signal Pharm Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
AU2017240050B2 (en) 2021-12-16
EP3436019B1 (en) 2021-07-28
CN109819649A (zh) 2019-05-28
CA3019105A1 (en) 2017-10-05
US20170283418A1 (en) 2017-10-05
EP3436019A1 (en) 2019-02-06
AU2017240050A1 (en) 2018-10-11
US10513519B2 (en) 2019-12-24
EP3436019A4 (en) 2019-08-28
RS62496B1 (sr) 2021-11-30
JP6995058B2 (ja) 2022-02-21
JP2019515889A (ja) 2019-06-13
LT3436019T (lt) 2021-10-25
CY1124677T1 (el) 2022-07-22
US20180362529A1 (en) 2018-12-20
DK3436019T3 (da) 2021-10-11
SI3436019T1 (sl) 2021-12-31
CN109819649B (zh) 2023-02-28
ES2895419T3 (es) 2022-02-21
PT3436019T (pt) 2021-11-04
MX2018011970A (es) 2019-05-20
HUE056631T2 (hu) 2022-02-28
US10047090B2 (en) 2018-08-14
EP3845536A1 (en) 2021-07-07
WO2017173218A1 (en) 2017-10-05
HRP20211546T1 (hr) 2022-01-07

Similar Documents

Publication Publication Date Title
LT3436019T (lt) (1s,4s)-4-(2-(((3s,4r)-3-fluortetrahidro-2h-piran-4-il)amino)-8-((2,4,6-trichlorfenil)amino)-9h-purin-9-il)-1-metilcikloheksan-1-karboksamidas ir jo naudojimo būdai
ZA201903932B (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase
EP3518934A4 (en) INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE
EP3443323A4 (en) DROPLET SORTER IN A HOUSING AND METHOD FOR USE THEREOF
EP3509590A4 (en) N-ACYL AMINO ACID COMPOUNDS AND METHOD OF USING
EP3474785A4 (en) SPINE IMPLANT AND METHOD FOR USE THEREOF
EP3558303A4 (en) AMINO ACID COMPOUNDS AND METHOD FOR USE
IL281089A (en) LINGO–1 antagonists and uses for the treatment of demyelinating disorders
EP3532528A4 (en) POLYAMIDES DERIVED FROM RENEWABLE SOURCES AND PROCESSES FOR THEIR PREPARATION
EP3472306A4 (en) IDENTIFYING A FACTOR TO PROMOTE SELF-RENEWAL OF HUMAN HSC
ZA201902781B (en) Compositions and methods for the treatment of xerostomia
EP3328380A4 (en) INHIBITOR COMBINATIONS OF BRUTON TYROSINE KINASE AND USES THEREOF
EP3466269A4 (en) COMPOSITION CONTAINING CAFFEINE AND CYCLOALANYLALANINE
EP3423060A4 (en) IMATINIB FOR USE IN THE TREATMENT OF STROKE
EP3724194C0 (en) SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
EP3651606A4 (en) PRECIOUS STONE COATINGS AND RELATED MANUFACTURING AND USE PROCEDURES
EP3554503A4 (en) PROTEIN 4 INHIBITORS CONTAINING BROMODOMAIN (BRD4)
HK1255695A1 (zh) 用於治療眼瞼下垂的組合物和方法
EP3440041A4 (en) SYNTHESIS OF 2'-FLUORO-6'-METHYLENE-CARBOCYCLIC ADENOSINE (FMCA) AND 2'-FLUORO-6'-METHYLENE-CARBOCYCLIC GUANOSIN (FMCG)
ZA201901505B (en) Phenylalanine-free protein for the treatment of pku
FI3724196T3 (fi) Substituoituja atsetidiinidihydrotienopyridiinejä ja niiden käyttö fosfodiesteraasin estäjinä
EP3528928A4 (en) FILTER ARTICLES AND METHOD OF MANUFACTURING AND USE THEREOF
EP3541571A4 (en) PLATE NAILING APPARATUS AND ASSOCIATED PROCESSES
SI3408264T1 (sl) Nilotinibijev dinitrat (V) in njegove kristalne oblike
EP3344239A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE